Anavex 2-73

Research use only, not for human use.

Anavex 2-73 is a Sigma-1 Receptor agonist (IC50: 860 nM).

Anavex 2-73 is a Sigma-1 Receptor agonist (IC50: 860 nM).(In Vivo):The pre-administration of Blarcamesine leads to a dose-dependent attenuation of the scopolamine induced alternation deficit, significant at 1 and 3 mg/kg. The pre-treatment with Blarcamesine hydrochloride attenuates the impairments of step-through latency, dose dependently and significantly at doses higher than 0.3 mg/kg. The Blarcamesine hydrochloride treatment dose-dependently blocks the recognition memory deficit, with a significant effect measured at 1 mg/kg. One day after injections, the significant Aβ25-35-induced decrease in Akt phosphorylation is significantly attenuated by Blarcamesine hydrochloride at 0.1 and 1 mg/kg dose. Seven days after injections, Blarcamesine hydrochloride attenuates the decrease in Ser9 phosphorylation induced by the peptide at 0.3 and 1 mg/kg. The Blarcamesine hydrochloride treatment dose-dependently prevents the Aβ25-35-induced increase in Aβ1-42 content, with a significant effect at the highest dose tested.

——

——

AE-37 hydrochloride

Others

Other Targets

σ1

Neurological Disease

——

195615-84-0

317.85

C19H24ClNO

>98% (HPLC)

DMSO : 37.5 mg/mL 117.98 mM;

CN(C)CC1CCOC1(C2=CC=CC=C2)C3=CC=CC=C3.Cl

——

(-20℃)

With Ice Pack

≥ 2 years